Abbott Laboratories (ABT)
$
124.3
-0.34 (-0.27%)
Key metrics
Financial statements
Free cash flow per share
3.9548
Market cap
216.4 Billion
Price to sales ratio
4.9347
Debt to equity
0.2540
Current ratio
1.7034
Income quality
0.6524
Average inventory
6.8 Billion
ROE
0.2824
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abbott Laboratories, along with its subsidiaries, is engaged in the discovery, development, manufacturing, and global sale of health care products, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The EBITDA is $10,834,000,000.00 a key indicator of the company's operational profitability. Within the Established Pharmaceutical Products segment, the company markets generic pharmaceuticals to address conditions such as pancreatic exocrine insufficiency and dyslipidemia, as well as providing critical anti-infectives like clarithromycin and an influenza vaccine. The operating expenses amount to $14,474,000,000.00 encompassing various operational costs incurred, while the company reported selling, general, and administrative expenses of $11,651,000,000.00 indicating its operational overhead costs. Furthermore, the diluted EPS is $7.64 accounting for potential share dilution. The Diagnostic Products segment enhances health care with laboratory systems focused on immunoassay and clinical chemistry, alongside molecular diagnostics for infectious agents. The Nutritional Products segment delivers essential nutritional solutions for both pediatric and adult populations, while the Medical Devices segment offers innovative treatments for cardiovascular diseases and diabetes management. Abbott Laboratories, founded in 1888 and based in North Chicago, Illinois, has established itself as a leader in the health care sector. The stock is reasonably priced at $136.04 appealing to a broad range of investors. With a large market capitalization of $216,351,767,974.00 the company is a dominant player in the health care industry, contributing significantly to the overall market landscape. The stock has a high average trading volume of 6,257,431.00 indicating strong liquidity. It is a key player in the Medical - Devices industry, driving innovation and growth, and belongs to the Healthcare sector, further affirming its stature within the competitive health care market. Abbott Laboratories’ commitment to advancement and quality in health care solutions continues to position it for sustained success and relevance.
Is Abbott Laboratories (ABT) a good investment?
Investing in Abbott Laboratories (ABT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Abbott Laboratories (ABT)'s stock forecast?
Analysts predict Abbott Laboratories stock to fluctuate between $110.86 (low) and $141.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abbott Laboratories's market capitalization?
As of 2026-01-14, Abbott Laboratories's market cap is $216,351,767,974, based on 1,740,561,287 outstanding shares.
How does Abbott Laboratories compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abbott Laboratories has a Lower Market-Cap, indicating a difference in performance.
Does Abbott Laboratories pay dividends?
Abbott Laboratories pays dividends. The current dividend yield is 1.93%, with a payout of $0.63 per share.
How can I buy Abbott Laboratories (ABT) stock?
To buy Abbott Laboratories (ABT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABT. Place an order (Market, Limit, etc.).
What is the best time to invest in Abbott Laboratories?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Abbott Laboratories stock ever split?
Abbott Laboratories's last stock split was 5000:2399 on 2013-01-02.
How did Abbott Laboratories perform in the last earnings report?
Revenue: $41,950,000,000 | EPS: $7.67 | Growth: 132.42%.
Where can I find Abbott Laboratories's investor relations reports?
Visit https://www.abbott.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abbott Laboratories?
You can explore historical data from here
What is the all-time high and low for Abbott Laboratories stock?
All-time high: $142.60 (2021-12-27) | All-time low: $89.67 (2023-10-12).
What are the key trends affecting Abbott Laboratories stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The latest trading day saw Abbott (ABT) settling at $124.64, representing a -1.02% change from its previous close.
seekingalpha.com
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.
zacks.com
In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.
prnewswire.com
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.
prnewswire.com
Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026 ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels.
defenseworld.net
Asset Management One Co. Ltd. raised its position in shares of Abbott Laboratories (NYSE: ABT) by 2.4% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 858,834 shares of the healthcare product maker's stock after buying an additional 19,966 shares during the
fool.com
Johnson & Johnson and Abbott Laboratories are diversified healthcare companies with attractive prospects. Both have raised their dividends for over 50 consecutive years.
zacks.com
ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.
fool.com
CVS Health is slowly righting the ship after several challenging years. Abbott Laboratories' strong business should improve thanks to an acquisition.
zacks.com
The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.
See all news
